Impact of interferon‐free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real‐life cohort. Issue 6 (27th February 2018)

• Record Type: Journal Article
• Authors: Álvarez‐Ossorio, M. J.; Sarmento e Castro, R.; Granados, R.; Macías, J.; Morano‐Amado, L. E.; Ríos, M. J.; Merino, D.; Álvarez, E. N.; Collado, A.; Pérez‐Pérez, M.; Téllez, F.; Martín, J. M.; Méndez, J.; Pineda, J. A.; Neukam, K.
• Other Names: Alados‐Arboledas Juan Carlos investigator.; Albendín Helena investigator.; Alemán María Remedios investigator.; Alonso María del Mar investigator.; Asensi Victor investigator.; Blanco María José investigator.; Cabo Rebeca investigator.; Camacho Ángela investigator.; Casas Mario Frías investigator.; Castro Ángeles investigator.; Cervantes Manuel investigator.; Cucurull Josep investigator.; Cuéllar Sandra investigator.; Cuenca Francisca investigator.; Delgado Marcial investigator.; Domínguez Lara investigator.; Dueñas Carlos investigator.; Fernández Elisa investigator.; Galera Carlos investigator.; Gálvez María Carmen investigator.; García Dácil investigator.; Martínez Paloma Geijo investigator.; Gómez Ana investigator.; Gómez Juan Luis investigator.; Gutiérrez Félix investigator.; Hernández José investigator.; Hernández Jehovana investigator.; Llenas‐García Jara investigator.; Márquez Manuel investigator.; Martínez Lorena investigator.; Martínez‐Álvarez Rosa investigator.; Madrid Onofre Martínez investigator.; Masiá María del Mar investigator.; Merchante Nicolás investigator.; Mínguez Carlos investigator.; Montero‐Alonso Marta investigator.; Omar Mohamed investigator.; Ortega Enrique investigator.; Padilla Sergio investigator.; Robledano Catarina investigator.; Pelazas Ricardo investigator.; Pérez‐Camacho Inés investigator.; Pernas Berta investigator.; Portilla Joaquín investigator.; Portu José Joaquín investigator.; Raffo Miguel investigator.; Real Luis Miguel investigator.; Reina Gabriel investigator.; Reus Sergio investigator.; Rincón Pilar investigator.; Rivero Antonio investigator.; Rivero‐Juárez Antonio investigator.; Romero‐Palacios Alberto investigator.; Rubio Purificación investigator.; Ryan‐Murua Pablo investigator.; Saíz de la Hoya Pablo investigator.; de los Santos‐Gil Ignacio investigator.; Santos Jesús investigator.; Saussol Fernando investigator.; Serrano Miriam investigator.; Toyas Carla investigator.; Vera‐Méndez Francisco Jesús investigator.; Hernández Marina Villalobos investigator.; García David Vinuesa investigator.;
• Is Part Of: Journal of viral hepatitis. Volume 25:Issue 6(2018)
• Page Start: 699
• Page End: 706
• Publication Date: 2018-02-27
• Subjects: direct antiviral agents -- glomerular filtration rate -- HCV -- HIV; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12867
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: Little data are available on renal toxicity exerted by direct‐acting antivirals (DAAs) in real life. The aim of this study was to assess the impact of direct‐acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR) in clinical practise. From an international, prospective multicohort study, patients treated with DAAs for at least 12 weeks and with eGFR ≥30 mL/min per 1.73 m 2 at baseline were selected. eGFR was determined using the CKD‐EPI formula. A total of 1131 patients were included; 658 (58%) were HIV/HCV‐coinfected patients. Among the 901 patients treated for 12 weeks, median (interquartile range) eGFR was 100 (87‐107) at baseline vs 97 (85‐105) mL/min per 1.73 m 2 at week 12 of follow‐up (FU12) post‐treatment ( P < .001). For HIV‐coinfected subjects who received tenofovir plus a ritonavir‐boosted HIV protease inhibitor (PI/r), baseline vs FU12 eGFR were 104 (86‐109) vs 104 (91‐110) mL/min per 1.73 m 2 ( P = .913). Among subjects receiving ombitasvir/paritaprevir with or without dasabuvir, eGFR did not show any significant change. Of 1100 subjects with eGFR >60 mL/min per 1.73 m 2 at baseline, 22 (2%) had eGFR <60 mL/min per 1.73 m 2 at FU12, but none presented with eGFR <30 mL/min per 1.73 m 2 . In conclusion, eGFR slightly declines during therapy with all‐oral DAAs and this effect persists up to 12 weeks after stopping treatment in subjects with normal to moderately impaired renal function, regardless of HIV status. Concomitant use of tenofovir plus PI/r does not seem to have an impact on eGFR.